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Computationally-guided optimization of small-
molecule inhibitors of the Aurora A kinase–TPX2
protein–protein interaction†
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Marko Hyvo¨nen, e David R. Spring, d David J. Huggins cdf and
William L. Jorgensen a
Free energy perturbation theory, in combination with enhanced
sampling of protein–ligand binding modes, is evaluated in the
context of fragment-based drug design, and used to design two
new small-molecule inhibitors of the Aurora A kinase–TPX2 protein–
protein interaction.
Aurora A is one of three human aurora kinases, a family of serine/
threonine kinases that play a central role in cell division.1 Aurora A
and Aurora B are critical for mitotic cell division, in which Aurora
C is also implicated2 alongside its role in meiosis.3 During mitosis,
Aurora A associates with the centrosome and the spindle micro-
tubules to control centrosome maturation and spindle assembly.4
It acts in part through direct phosphorylation of partners such as
PLK1.5 Aurora A is ubiquitously expressed but its expression is
strongly cell cycle dependent. Its expression peaks at the G2-M
transition, when it is involved in the mitotic checkpoint.6 Aurora A
is a 403-residue protein, composed of an N-terminal domain, a
protein kinase domain, and a C-terminal domain. The N-terminal
and C-terminal domains contain a KEN degradation motif and a
destruction box (D-box) respectively, both of which control
degradation.7 Aurora A is oncogenic and is overexpressed in
tumors of the breast, colon, stomach, and ovaries.8 Inhibition of
Aurora A leads to cell death in dividing cells, through amechanism
involving chromosome misalignment and stalling at the mitotic
checkpoint.9,10 As a consequence, it has received a lot of attention
as a potential drug target in cancer7 and numerous kinase
inhibitors have been described.11–13 A number of these inhibitors
are now in clinical trials.11 As well as the ATP-binding site, an
additional allosteric binding site can also be targeted to modulate
Aurora A function.14 During mitosis, Aurora A is localized to
microtubules in themitotic spindle through an interaction between
the kinase domain and the protein TPX2.15 The N-terminal
sequence of TPX2 binds to an allosteric pocket on Aurora A16
and stimulates kinase activity, leading to cell-cycle progression.
Interruption of the Aurora A–TPX2 interaction reduces kinase
activity, leading to mislocalization of Aurora A, mitotic defects,
and cell cycle arrest.17
In previous work, some of us have described the development of
small-molecule inhibitors targeting the TPX2 binding pocket of
Aurora A.18 In particular, through a process of high-throughput
screening of diverse chemical libraries19 and fragment deconstruc-
tion, the fragment 2-phenyl-4-carboxyquinoline (compound 1,
Fig. 1) was developed. Compound 1 shows a dose-dependent
inhibition of TPX2 binding to Aurora A in a fluorescence
anisotropy (FA) assay (Ki = 63 mM). A process of synthesis and
investigation of structure–activity relationship (SAR) trends was
Fig. 1 Crystal structure of AurkinA (compound 13) bound to Aurora A
kinase.18 Flexible torsional angles in the ligand (f) and L178 on the protein
(w) are shown in red.
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embarked upon to improve the potency of the fragment, mainly
through increasing the hydrophobicity of the phenyl group which
occupies the pocket formed by residues L178, V182, V206 and L208
(Fig. 1). The most potent molecule, named AurkinA (Ki = 2.7 mM),
was shown to inhibit the kinase activity of Aurora A in vitro and
mislocalize Aurora A from mitotic spindle microtubules in vivo.18
AurkinA provides a blueprint for future design efforts that target
the TPX2 binding pocket of Aurora A.
Free energy perturbation (FEP) theory for the computation of
relative binding free energies is a promising companion for the
fragment-based drug discovery (FBDD) techniques used above
(see the ESI†). In FBDD, improvement of the binding aﬃnity is
the most important factor and multiple rounds of synthesis are
often required to obtain the requisite potency gains.20 However,
for fragments that bind with mM to high mM aﬃnity it is often
diﬃcult to accurately measure binding constants in biological
assays and hence pursue SAR. These technical problems should
not aﬀect the accuracy of FEP methods and hence eﬃciency
gains in the FBDD process are expected if X-ray crystallography
and computational predictions are used in tandem. A recent
study of the binding of 90 small molecules to a range of targets
revealed that FEP is able to predict relative binding aﬃnities in
FBDD studies with root mean square (RMS) errors of approxi-
mately 1.1 kcal mol1.21
The MCPRO software22 is a widely used tool for quantitative
predictions of relative binding free energies, which uses FEP
theory in combination with Monte Carlo sampling (MC/FEP).
Notable successes include the prediction of a number of extremely
potent inhibitors of HIV reverse transcriptase23 and macrophage
migration inhibitory factor.24 However, it has not been used
before now to our knowledge in FBDD eﬀorts. A potential hurdle
to its uptake is the possibility of a range of dynamic binding
modes that are available to small, flexible fragments. In the
current study for example the flexibility of the phenyl-quinoline
linker (Fig. 1) means that groups added to the phenyl ring may
orient either toward or away from the hydrophobic floor of the
binding pocket. Furthermore, as we shall show, the addition of
the bulky groups to the ligand may induce re-orientation of the
L178 side chain, in a manner reminiscent of the V111 side chain
rotation in the T4 lysozyme model system, which has been shown
to be problematic for standard FEP simulations.25
In what follows, we describe the application of MCPRO, in
combination with the recently implemented replica exchange with
solute tempering (REST) enhanced sampling method,26–29 to the
study of the relative affinities of 14 small molecule inhibitors of
Aurora A. The REST algorithm has been shown to substantially
improve the consistency of MC/FEP results by improving conforma-
tional sampling, thereby reducing dependency on the choice of
starting structure.28 The computed conformational ensembles have
additionally been shown to be in excellent agreement with mole-
cular dynamics simulations.29 Here, the REST method successfully
incorporates torsional sampling of both the phenyl group and L178
side chain in a single simulation and recapitulates the experi-
mental binding data in the majority of cases. In addition, we make
two new experimentally-verified predictions, one of which yields
a small molecule inhibitor that is equally potent as AurkinA.
This study points to the potential for routine use of MC/FEP in
prospective fragment-based lead optimization.
Optimization of the binding potency of small molecule
analogs of compound 1 was initially pursued by investigating
substituents at the meta and para positions of the phenyl ring
(see the ESI†). The asymmetric substitutions pose a problem for
traditional FEP simulations, since the simulation firstly needs to
find the preferred binding pose (e.g. Fig. 2(a and b)), which is not
necessarily known a priori, and secondly needs to account for the
entropic penalty associated with the loss of symmetric binding
modes.30 The REST algorithm implemented in MCPRO accounts
for both of these factors by eﬀectively enhancing the sampling of
dihedral angle ‘flips’ between alternative binding modes.28
In addition, our crystallographic data are inconclusive concerning
which of the two rotamers of L178 shown in Fig. 2(a and c) is
preferred for a given substituent. Previous crystallographic
studies of the T4 lysozyme hydrophobic cavity have shown that
the size of the binding pocket is strongly influenced by the size of
the bound ligand31 and computational estimates of binding aﬃnity
can be strongly dependent on the choice of starting structure.25,32
Here, initial estimates of the binding free energy of a Cl substituent
at the meta position, relative to F, gave 0.27 kcal mol1 starting
from the structure shown in Fig. 2(a) and 0.78 kcal mol1
Fig. 2 Examples of structures sampled during MC/FEP simulations
of compound 2 bound to Aurora A. (a) f = 1801, w = 1801, (b) f = 3301,
w = 1801, (c) f = 1801, w = 601.
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starting from the structure in Fig. 2(c). We have therefore added
the residue L178 to the REST enhanced sampling region and
allowed flips in the angle w during our simulations (Fig. 1). The
computed binding free energy of Cl, relative to F, is then
independent of the choice of starting structure (0.73 and
0.80 kcal mol1 respectively).
Table 1 shows the comparisons between computation
(including both the ligand and residue L178 in the REST region)
and experimental FA assays.18 In general, it can be seen that
adding halogens at the position X is predicted to be favorable. In
particular, with the enhanced sampling of L178, the prediction
Br4 F4H is in line with experimental results. X = Cl is actually
predicted to be more potent than X = Br, but compound 4 has
not been synthesized. The additional substitution of Z = F is also
found to enhance binding relative to Z = H.
To demonstrate the conformational sampling facilitated by
the REST method, Fig. 3 shows the distribution of dihedral
angles in simulations of 2 and 5 bound to Aurora A. Compound
2 samples all of the conformations shown in Fig. 2 with a
preference for f = 3301 and w = 1801 (Fig. 2(b)). In contrast,
binding of 5 with the bulkier Cl in the meta position leads to a
reorientation of the L178 side chain (w = 601). There is a slight
preference for Cl to be oriented toward the hydrophobic floor of
the binding pocket (w = 1801) but both conformations of the
phenyl group are sampled. In order to check the orientation
of the small molecules in the binding pocket, we have collected
X-ray crystal structures of 2 and 5 (see the ESI†). In contrast to
the MC simulations, both crystal structures clearly show that f is
close to 1801. The discrepancy is possibly due to force field
inaccuracy, crystallization conditions, or a small population of
alternative conformations may not be visible in the X-ray electron
density. It is more diﬃcult to assign the orientation of the L178
side chain, and so the inter-conversion between the two popula-
tions observed in the MC simulations may be accurate.
Returning to the prediction of relative binding free energies, the
substitution of bulkymethyl and trifluoromethyl at themeta position
was predicted to be less favorable than compound 1, although 7
showed reasonable activity experimentally (Table 1). On the basis of
the computational data 8 was not pursued further. Interestingly,
however, there does appear to be space to accommodate a methyl
substitution in the TPX2 pocket at the para position on the phenyl
ring. In particular, compounds 9 and 10 show enhanced activity in
FEP simulations relative to 2 and 6, respectively. As a result of these
predictions, compounds 9 and 10were synthesized and assayed (see
the ESI†), resulting in the most potent fragment reported here
(compound 10, Ki = 2.3 mM). As predicted, compound 9 also shows
enhanced activity relative to 2.
Encouraged by these results, we tested four more compounds
with potential benefits (Fig. 4). Compound 11 introduces an
electronegative N atom into the TPX2 binding pocket, but this
Table 1 Comparisons between computed relative free energies of bind-
ing (DDG) and experiment18
X Y Z DDGa IC50
b Ki
b
1 H H H 1.05 289 62.5
2 F H H 0.00 75.9 16.5
3 F H F 0.94 36.0 7.8
4 Cl H H 0.73 ND ND
5 Cl H F 0.89 20.5 4.4
6 Br H H 0.49 25.6 5.5
7 CF3 H H 0.11 26.5 5.7
8 CH3 H H 1.12 ND ND
9 F CH3 H 0.49 42c 8.7c
10 Br CH3 H 0.90 11.1c 2.3c
a kcal mol1. b mM. c This work (see the ESI).
Fig. 3 Dihedral angle distributions from Monte Carlo simulations for both
the phenyl ring of compounds 2 and 5 (f) and the side chain of L178 (w).
Assigned dihedral angles from X-ray crystal structures are displayed as
vertical dashed lines.
Fig. 4 Additional MC/FEP relative free energies of binding (kcal mol1)
and experimental results where available.18
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is predicted to be unfavorable. This result is in qualitative agree-
ment with the SAR presented in ref. 18 for a set of related
molecules. Compound 12 was expected to orient the ligand for
optimal binding in the Aurora A binding pocket. However, the
relative binding free energy was predicted to be similar to 6 and so
was not pursued further. As a further test of the FEPmethodology,
the relative binding free energy of AurkinA (compound 13)
was computed. In agreement with experiment, the F substituent
on the quinoline was extremely favorable. A similar substitution
on compound 10 may improve its potency still further. Finally,
compound 14 showed good predicted activity but could not be
synthesized so far.
As a means of benchmarking computational methodologies, it
is commonplace to compare computed DDG with experimental
pIC50.
21,30 Fig. 5 compares the computed and experimental results
where available. The mean unsigned error is 0.24 kcal mol1, the
root-mean-square error is 0.32 kcal mol1, and the Pearson
correlation coeﬃcient is 0.86. The largest errors are for com-
pounds 3 and 7, but even these are relatively small. Perhaps most
encouragingly for the use of FEP as a computational pre-screening
tool, the three most potent fragments (5, 10 and 13) are in the
top four computational predictions.
In summary, the replica exchange with solute tempering
method for the enhanced sampling of both protein and small
molecule degrees of freedom has been implemented in MCPRO
and used for the first time in FBDD to rank inhibitors of the
Aurora A–TPX2 protein–protein interaction. The utility of the
method is demonstrated by the experimentally-verified prediction
of two novel small-molecule inhibitors (compounds 9 and 10),
one of which is as potent as AurkinA.18 More generally, FEP shows
promise as a pre-screening tool for use in prospective fragment-
based drug design efforts, especially when combined with
enhanced sampling of protein–ligand binding modes.
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